Weekly treatment with nab-paclitaxel was generally well-tolerated, as adverse events were similar in patients ≥70 years old vs the entire study population, with fewer grade 3/4 neutropenia events (P<0.05) and neuropathy events (P<0.05), in the nab-P/C vs sb-P/C arms. This study represented a unique standalone observation in that there were not a lot of other NSCLC presentations at ASCO 2012 that focused on the influence of different types of chemotherapy on the elderly population.

Dr. Socinski concluded: “From this subgroup analysis, it is a win-win situation for the older patients because of the better survival rates and toxicity profile that is a bit more favorable.” However, he added that “the nab-paclitaxel was delivered on a weekly basis and the solvent-based paclitaxel was delivered every 3 weeks. So, even though there was difference in schedule in the randomization, I don’t think that weekly schedules are really a significant drawback to every 3 week schedules anymore.” This study was recently published in the Journal of Clinical Oncology.


Continue Reading


REFERENCES

1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2008 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2012. http://www.cdc.gov/uscs. Accessed July 2, 2012.

2. American Cancer Society. Cancer Facts and Figures 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed July 2, 2012.

3. Kim ES, Neubauer MA, Cohn AL, et al. SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy. Paper presented at: American Society of Clinical Oncology Annual ’12 Meeting; June 1-5, 2012; Chicago, IL. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=92436. Accessed July 2, 2012.

4. Yang J, Schuler MH, Yamamoto N, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Paper presented at: American Society of Clinical Oncology Annual ’12 Meeting; June 1-5, 2012; Chicago, IL. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=91942. Accessed July 2, 2012.

5. Seiwert T, Fayette J, Cupissol D, et al. LBPV10 – A Randomized, Open-label, Phase Ii Study Of Afatinib (bibw 2992) Versus Cetuximab In Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck – Final Data. Paper presented at: Multidisciplinary Head and Neck Cancer Symposium; January 26-28, 2012; Phoenix, AZ. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=b1c590bb-c362-40ea-bf96-b8f21b8936d8&cKey=3ad77ae1-570c-47c9-b67c-4eb2409785ce&mKey={82897973-8A41-4F26-BB8E-7E358FC53B94}. Accessed July 2, 2012.

6. Socinski MA, Langer CJ, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC). Paper presented at: American Society of Clinical Oncology Annual ’12 Meeting; June 1-5, 2012; Chicago, IL. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100901. Accessed July 2, 2012.